Last updated on July 2019

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Brief description of study

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

Clinical Study Identifier: NCT02974725

Find a site near you

Start Over

Novartis Investigative Site

Villejuif Cedex, France
  Connect »